Blog
RSS FeedPosted by Michael Wonder on 03 Sep 2016
FDA approves Blincyto (blinatumomab) for use In paediatric patients with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
1 September 2016 - Amgen today announced that the U.S. FDA has approved the supplemental biologics license application for Blincyto (blinatumomab) ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 01 Sep 2016
Genmab announces U.S. FDA approval of Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide for relapsed CLL
31 August 2016 - Arzerra now approved by U.S. FDA for use in combination with fludarabine and cyclophosphamide in relapsed CLL ...
Posted by Michael Wonder on 31 Aug 2016
TGA approves new diagnostic agent
31 August 2016 - The TGA has approved Juno Pharmaceuticals' Hexvix. ...
Posted by Michael Wonder on 31 Aug 2016
Xalkori (crizotinib) receives approval in European Union for the treatment of patients with ROS1-positive advanced non-small cell lung cancer
31 August 2016 - Xalkori is the first and only approved biomarker-driven therapy for ROS1-positive advanced non-small-cell lung cancer in the ...
Posted by Michael Wonder on 31 Aug 2016
TGA approves Zepatier
31 August 2016 - The TGA has approved MSD's Zepatier (grazoprevir with elbasvir). ...
Posted by Michael Wonder on 30 Aug 2016
FDA approves Sandoz Erelzi to treat multiple inflammatory diseases
30 August 2016 - Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine. ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends Brilinta (ticagrelor)
25 August 2016 - CADTH has recommended the reimbursement of AstraZeneca's Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events. ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada. ...
Posted by Michael Wonder on 30 Aug 2016
Seqirus receives FDA approval for Afluria Quadrivalent (influenza vaccine) for people 18 years of age and older
29 August 2016 - Seqirus is shipping trivalent and quadrivalent formulations of Afluria in the 2016-2017 influenza season. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends against the reimbursement of Egrifta (tesamorelin acetate)
24 August 2016 - CADTH is not convinced that Egrifta should be reimbursed in Canada. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)
24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...
Posted by Michael Wonder on 28 Aug 2016
Amgen's shameful silence covers up reasons for FDA drug rejection
25 August 2016 - An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. FDA but the company has offered ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of secukinumab (Cosentyx) for ankylosing spondylitis
23 August 2016 - CADTH publishes second outcome for Cosentyx this month. ...